NYSE
$39.03▼ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $131.28BShares out 33.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 6d agoPre-market26.10.19 21:316-KKey event#●●●#●●●
NOVO NORDISK A SBullish
Novo Nordisk is executing a share repurchase program of up to DKK 15 billion over a 12-month period starting February 4, 2026, having repurchased 1,225,000 B shares between October 12 and October 16. As of October 16, 2026, the company has repurchased a total of 39,074,179 B shares for approximately DKK 10.88 billion, with treasury shares now accounting for 1.2% of total share capital.…more
$39.03-0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 19:156-KKey event
NOVO NORDISK A S
Novo Nordisk repurchased 1,245,000 B shares between October 5 and October 9, 2026, as part of its 15 billion DKK share repurchase program initiated on February 4, 2026. To date, the company has repurchased a total of 37,849,179 B shares at an average price of 278.97 DKK, representing a total transaction value of 10,558,876,422 DKK.…more
$39.03-0.04%vs prev closeView filingShare - 10.6Pre-market26.10.06 21:116-KKey event
NOVO NORDISK A S
Novo Nordisk is executing a share repurchase programme of up to DKK 15 billion over a 12-month period starting February 4, 2026, including a specific B-share buyback of up to DKK 11.2 billion from May 6, 2026, to February 1, 2027. As of October 2, 2026, the company has repurchased a total of 36,604,179 B shares at an average price of DKK 279.95, bringing its total treasury shares to 50,644,876, representing 1.1% of the share capital.…more
$39.03-0.04%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 03:24Bullish#●●●#●●●
Novo Nordisk's Awiqli Receives FDA Approval for Pediatric Type 2 Diabetes…more
The FDA has approved Novo Nordisk's Awiqli as the first once-weekly insulin treatment for pediatric patients aged 10 and older with type 2 diabetes. This approval marks a significant advancement in improving treatment adherence for young patients.…more
$39.03-0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 20:01
●●●●●●●● ●●●●● ●●●●●●
More than half of U.S. GLP-1 users now take the medication for weight management, driving significant shifts in dietary habits and discretionary spending. This structural change is forcing food manufacturers and apparel retailers to adapt their product offerings and shelf strategies.…more
$39.03-0.04%vs prev closeShareBenzinga - 2d agoPre-market26.10.23 18:58
●●●●●●●● ●●●●● ●●●●●●
Dr. Reddy's has introduced new generic versions of Ozempic to capitalize on current supply shortages. This move aims to capture market share while competitors face distribution challenges.…more
$39.03-0.04%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report